Nicole Daley

Nicole Daley

Goodwin

Contact
View Bio
RSS

Latest Posts › FDA Approval

Share:

Coherus Announces FDA Approval of CIMERLI (ranibizumab-eqrn)

​​​​​​​On August 2, 2022,  Coherus BioSciences, Inc. announced that the FDA approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar interchangeable with LUCENTIS® (ranibizumab injection) for all five indications, with 12 months...more

8/5/2022  /  Biosimilars , Coherus , FDA Approval , Food and Drug Administration (FDA) , Pharmaceutical Industry , Prescription Drugs
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide